Vanguard Asset Management’s Immunovant IMVT Stock Holding History
Bought
Maintained
Sold
Other funds holding IMVT
Vanguard Asset Management's IMVT Position: Q3 2026 in Review
Vanguard Asset Management increased its Immunovant (IMVT) stake by 6% in Q3 2026, buying an estimated $152K and bringing the position to 68,650 shares worth $2.32M. The position accounts for ﹤0.01% of the portfolio, ranked #1485.
Vanguard Asset Management first reported a position in IMVT in Q1 2026 and has held it in 3 quarters since. The position peaked at $2.5M in Q2 2026. 232 funds tracked by Wall St. Rank hold IMVT as of Q3 2026.
- Vanguard Asset Management held 68,650 shares of Immunovant worth $2.32M as of Q3 2026.
- Vanguard Asset Management bought 3,859 Immunovant shares in Q3 2026, an estimated $152K.
- Immunovant made up ﹤0.01% of Vanguard Asset Management's portfolio in Q3 2026, its #1485 holding.
- Vanguard Asset Management first reported a position in Immunovant in Q1 2026 and has held it in 3 quarters since.
- Vanguard Asset Management's Immunovant position peaked at $2.5M in Q2 2026.
- 232 funds tracked by Wall St. Rank held Immunovant as of Q3 2026.
Based on Vanguard Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.